Navigation Links
ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis
Date:12/7/2009

ase. ATS Medical serves the cardiac surgery community by focusing on two distinct but operationally synergistic market segments: heart valve disease therapy and surgical ablation of cardiac arrhythmias.

ATS was originally founded to develop the ATS Open Pivot® Heart Valve as a new mechanical heart valve standard of care. Today the ATS Open Pivot Heart Valve is the preferred mechanical heart valve in many markets around the world and the fastest growing mechanical prosthesis in the market. Building on this legacy and addressing the largest market segment in heart valve therapy, the ATS 3f® brand encompasses an innovative tissue heart valve portfolio to address conventional open surgery requirements as well as the growing demand for less invasive sutureless based procedures. The ATS 3f® portfolio includes offerings at various stages including early product development, pivotal clinical trials, and market commercialization. Completing the portfolio in heart valve therapy is the ATS Simulus® annuloplasty product line. Simulus products assist the surgeon in repairing a patient's native heart valve as an alternative to replacement. Continuing ATS Medical's focus on serving the cardiac surgery community are the ATS CryoMaze® products for surgical cryoablation of cardiac arrhythmias. ATS CryoMaze® products are used by surgeons to treat patients suffering from cardiac arrhythmias, the largest and fastest growing form of structural heart disease in populations over 60 years of age. The ATS Medical web site is http://www.atsmedical.com.

Safe Harbor

This Press Release contains forward-looking statements that may include statements regarding intent, belief or current expectations of the Company and its management. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of important factors, including
'/>"/>

SOURCE ATS Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Alberta companies delivering new products to the health & medical marketplace
2. Inverness Medical Innovations Declares Dividend on its Series B Convertible Perpetual Preferred Stock
3. Medical Research Leaders Explore Novel Strategies to Expedite the Search for Cures
4. Gamida Cell Announces Feasibility Study With Weill Cornell Medical College
5. New Jerseys Best and Brightest Minds Discuss Challenges Facing Medical Innovation, Call for Policies to Preserve U.S. Leadership in Research and Development
6. PacsDrive Announces Low Cost Medical Imaging Storage Service, Seeks to Alter Status Quo in Health Care IT
7. Aethlon Medical to Present at LD MICRO Conference on December 3, 2009
8. China Sky One Medical, Inc. Signs Distribution Agreement with MDK for the Sale of Two Diagnostic Kits in Southeast Asia
9. ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ
10. Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence
11. Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2015)... , March 29, 2015  Caris ... study data in small cell cervical cancer ... Caris Molecular Intelligence®, the company,s panomic, comprehensive ... gene mutations which may explain sensitivities and ... that identification of certain biomarkers may guide ...
(Date:3/27/2015)... RI (PRWEB) March 27, 2015 Earlier ... for the promotion of hair regrowth in adult men ... classifications I-II or Norwood Hamilton classifications of IIa-V and ... an industry plagued by products that over-promise and under-deliver, ... Capillus272Pro™, renewing faith and confidence among more than 80 ...
(Date:3/27/2015)... -- Neogen Corporation (NASDAQ: NEOG ) announced today that ... in accordance with Securities and Exchange Commission rule 10b5-1. ... Corporation, is a minority owner of this entity that ... Herbert does not have control of this entity, but ... for a portion of the shares owned by that ...
(Date:3/27/2015)... , March 27, 2015 Working ... Free Hospital in London , Richmond Pharmacology ... a global Phase 3 study for an investigational RNAi therapeutic ... orphan disease affecting the nerves and heart. ... Detail Based at St Georges University of ...
Breaking Biology Technology:Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 2Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 3Dr. Robert Leonard Applauds FDA Clearance of Capillus272Pro™ Hair Loss Laser Cap 2Neogen CEO adopts 10b5-1 Trading Plan 2
... Leonhardt,s Launchpads ( www.leonhardtslaunchpads.com ), at the ... Center ( www.uncm.edu/STIC.php ), 2330 Circadian Way, Santa ... Grand Opening on Tuesday, November 9th from 3pm ... incubator for startup businesses and high-potential entrepreneurs in ...
... Inc. Prices $50 Million Public Offering ... ... lpUnit=,PRN,; --> ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var ...
... Davis Phinney Foundation ( http://www.davisphinneyfoundation.org ), a non-profit foundation ... help people to live well with Parkinson,s disease, today ... Exercise and Parkinson,s: Questions and Answers from the Experts ... experts in the fields of physical therapy and exercise ...
Cached Biology Technology:OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering 2OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering 3OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering 4OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering 5OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering 6OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering 7OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering 8OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering 9Davis Phinney Foundation Launches Exercise-Focused Tools to Help People Live Well With Parkinson's Disease 2Davis Phinney Foundation Launches Exercise-Focused Tools to Help People Live Well With Parkinson's Disease 3Davis Phinney Foundation Launches Exercise-Focused Tools to Help People Live Well With Parkinson's Disease 4
(Date:3/10/2015)... 10, 2015 Transforming How We ... "Personalized Medicine in Human Space Flight" by ... Goodwin , Ph.D. was recently featured by Springer Science ... years. Specifically, "Personalized Medicine in Human Space ... published in 2013 and 2014 from Springer in the ...
(Date:3/5/2015)... SAO PAULO , March 5, 2015 In ... with 41 percent of companies already using these solutions and ... of 2015. Of the latter, approximately 25 percent of the ... time. While the majority of companies in the ... is anticipated that the hybrid model will command significant attention ...
(Date:3/2/2015)... March 2, 2015 Synaptics Inc. (NASDAQ: ... human interface solutions, today announced a new implementation ... to enable rapid and secure transactions and reliable ... gaming is a turnkey solution providing mouse and ... quickly integrate fingerprint ID solutions into their product ...
Breaking Biology News(10 mins):"Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3
... risk of acquiring HIV rises during pregnancy, according to ... by researchers at the Johns Hopkins Bloomberg School of ... even after researchers controlled for behavior and other factors ... published in the September 30, 2005, edition of The ...
... trial, a new drug that selectively blocks immune ... kidney transplant rejection as cyclosporine, the standard anti-rejection ... drug, a co-stimulatory blocker called belatacept (LEA29Y), also ... the toxic side effects associated with standard anti-rejection ...
... have tracked down the biological trigger that gives ... bone disorder that can cause blindness and deafness. ... and could lead to new treatments for osteoporosis ... team from Lawrence Livermore and Lawrence Berkeley national ...
Cached Biology News:Pregnant women at higher risk for HIV, Uganda study finds 2New type of rejection blocker protects kidneys after transplant 2New type of rejection blocker protects kidneys after transplant 3New type of rejection blocker protects kidneys after transplant 4Researchers track down cause of a disfiguring bone disorder 2Researchers track down cause of a disfiguring bone disorder 3
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
TXNL2 Antibody...
Biology Products: